10th International Symposium on Advanced Ovarian Cancer: Optimal Therapy. Update
6 March 2015
Valencia, Spain
Guest Editors: A. Poveda, J. B. Vermorken and A. Cervantes

www.annonc.oxfordjournals.org
www.esmo.org
www.jsmo.or.jp
Annals of Oncology
Official Journal of the European Society for Medical Oncology and the Japanese Society of Medical Oncology

editor-in-chief:
J.-C. Soria, Villejuif, France

associate editors
Breast tumors
F. André, Villejuif, France
C. Sotiriou, Brussels, Belgium
Thoracic tumors
T. Mitsudomi, Osaka, Japan
J. F. Vansteenkiste, Leuven, Belgium
Head and neck tumors
A. T. C. Chan, Shatin, Hong Kong

editors emeriti
F. Cavalli, Bellinzona, Switzerland
D. J. Kerr, Oxford, UK
J. B. Vermorken, Edegem, Belgium
Melanoma
G. Long, Sydney, Australia
Hematological malignancies
K. Tsukasaki, Kaiishi, Japan
Supportive care
K. Jordan, Halle, Germany
Epidemiology
P. Boffetta, New York, New York, USA
Sarcoma and clinical pharmacology
O. Mir, Villejuif, France
Early drug development
J.-C. Soria, Villejuif, France

executive editor: Lewis Rowett
editorial office: Vanessa Marchesi, Paola Minotti Bernasconi, Giovannella Porcu, Annals of Oncology, Via Luigi Taddei 4, CH-6962 Viganello-Lugano, Switzerland

Annals of Oncology is covered in C.A.B. International, Current Clinical Cancer, Current Contents/Clinical Medicine*, Current Contents/Life Sciences, Elsevier BIOBASE/Current Awareness in Biological Sciences, EMBASE/Excerpta Medica, IBIDS, Index Medicus/MEDLINE, The International Monitor in Oncology, Medical Documentation Service, Science Citation Index* and Science Citation Index Expanded.
Annals of Oncology

Official Journal of the European Society for Medical Oncology and the Japanese Society of Medical Oncology

Volume 27, 2016 Supplement 1

10th International Symposium on Advanced Ovarian Cancer: Optimal Therapy. Update

6 March 2015, Valencia, Spain

Guest Editors:

A. Poveda*
Fundación Instituto Valenciano de Oncología, Valencia, Spain

J. B. Vermorken**
Department of Oncology, Universitair Ziekenhuis Antwerpen, Edegem, Belgium

A. Cervantes***
Biomedical Research Institute, INCLIVA, University of Valencia, Valencia, Spain

Note. The articles published in this supplement of Annals of Oncology represent the presentations made at the 10th International Symposium on Advanced Ovarian Cancer: Optimal Therapy. Update held in Valencia, Spain on 6 March 2015. Original data presented may have been subsequently published elsewhere. All manuscripts submitted to this supplement have been subjected to peer review, and authors have been requested to disclose any relationships with companies whose products or services are discussed in their manuscript. Disclosed information is indicated as a footnote in each article.

*Dr Poveda has reported no conflicts of interest.

**Professor Vermorken has reported that he has presented data on trabectedin for PharmaMar for which he has received an honorarium.

***Dr Cervantes has acted as a consultant or advisor to Amgen, Astra Zeneca, Sanofi-Aventis, Merck Serono, MSD, Genentech, and Roche.

Funding: The publication of this supplement and the symposium on which it is based have been supported through partnership between the Spanish Ovarian Cancer Research Group (GEICO) and the European Society for Medical Oncology (ESMO).